Milk Fat Globule Membrane Supplementation in Children: Systematic Review with Meta-Analysis

Dominika Ambrożej1,2, Karolina Dumycz1,2, Piotr Dziechciarz3

  • 1Department of Pediatric Pneumonology and Allergy, Medical University of Warsaw, 02-091 Warsaw, Poland.

Nutrients
|March 6, 2021
PubMed

Insights

Milk fat globule membrane (MFGM) supplementation in infant formula is safe and shows potential benefits for infant growth, mirroring breast milk effects. Further research is needed to confirm promising impacts on immunity and cognition.

Area of Science:

  • Pediatrics
  • Nutrition Science
  • Immunology

Background:

  • Milk fat globule membrane (MFGM) is crucial for lipid transport in breast milk and possesses immunological and antimicrobial properties.
  • Standard infant formulas lack MFGM due to processing, potentially missing key bioactive components.
  • MFGM supplementation in infant formula aims to replicate breast milk's benefits.

Purpose of the Study:

  • To evaluate the safety and efficacy of MFGM supplementation in infant formulas.
  • To compare growth parameters and other health outcomes in infants receiving MFGM-supplemented formula versus standard formula or breast milk.

Main Methods:

  • A systematic literature search was conducted across four databases for randomized controlled trials.
  • Seventeen studies involving 24 publications were included in the meta-analysis.
  • Primary outcomes focused on growth parameters at 4 months of age.

Main Results:

  • MFGM-supplemented formulas demonstrated non-inferior growth compared to standard formulas.
  • Infant growth outcomes in MFGM-supplemented formulas were more similar to those of breastfed infants.
  • No significant adverse effects were reported, indicating a good safety profile.

Conclusions:

  • MFGM supplementation in infant formula appears safe and may offer beneficial effects.
  • Promising findings regarding reduced acute otitis media and enhanced cognitive development require further investigation.
  • Well-designed clinical trials are necessary to definitively establish the benefits of MFGM supplementation.

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
95
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
87
Lipid Absorption01:24

Lipid Absorption

Dietary triglycerides from chyme in the duodenum are mixed with bile salts produced by the liver to emulsify fats. As a result, large droplets are broken down into smaller ones, increasing the surface area for enzymatic action. Once emulsified, pancreatic lipases hydrolyze the triglycerides into free fatty acids and monoglycerides.
These breakdown products bind with bile salts and lecithin to form micelles, which quickly pass between microvilli to come in close contact with the apical...
2.0K
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
100
Overview of Fatty Acid Metabolism01:28

Overview of Fatty Acid Metabolism

Lipids also are sources of energy that power cellular processes. Like carbohydrates, lipids are composed of carbon, hydrogen, and oxygen, but these atoms are arranged differently. Most lipids are nonpolar and hydrophobic. Major types include fats and oils, waxes, phospholipids, and steroids.
Fatty acids are catabolized in a process called beta-oxidation, which takes place in the matrix of the mitochondria and converts their fatty acid chains into two-carbon units of acetyl groups. The acetyl...
33.4K
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
118